Translational rodent paradigms to investigate neuromechanisms underlying behaviors relevant to amotivation and altered reward processing in schizophrenia

Schizophrenia Bulletin

Volumn 41, Issue 5, 2015, Pages 1024-1034

  Young, Jared W ^a,b   Markou, Athina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTIVATION; BEHAVIOR; COGNITION; DECISION MAKING; FEEDBACK SYSTEM; HUMAN; LEARNING; MOTIVATION; NEUROSCIENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; REWARD; RODENT; SCHIZOPHRENIA; TASK PERFORMANCE; TRANSLATIONAL RESEARCH; ANIMAL; DISEASE MODEL; INSTRUMENTAL CONDITIONING; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; HUMANS; MOTIVATION; NEUROPSYCHOLOGICAL TESTS; REWARD; RODENTIA; SCHIZOPHRENIA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84943152161     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv093     Document Type: Review

References (106)

1. Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatry. 1996;60:604-613.
2. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004;72:5-9.
3. Carter CS, Barch DM. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull. 2007;33:1131-1137.
4. Sahakian BJ, Owen AM, Morant NJ, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl). 1993;110:395-401.
5. Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia. 1991;29:993-1006.
6. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
7. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull. 2011;37:250-254.
8. Laughren T, Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr Bull. 2011;37:255-256.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
10. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238-245.
11. Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr Bull. 2006;32:246-249.
12. Rassovsky Y, Horan WP, Lee J, Sergi MJ, Green MF. Pathways between early visual processing and functional outcome in schizophrenia. Psychol Med. 2011;41:487-497.
13. Horan WP, Kring AM, Blanchard JJ. Anhedonia in schizophrenia: a review of assessment strategies. Schizophr Bull. 2006;32:259-273.
14. Green MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry. 2012;69:1216-1224.
15. Ellenbroek BA, Cools AR. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol. 2000;11:223-233.
16. Young JW, Zhou X, Geyer MA. Animal models of schizophrenia. In: Swerdlow NR, ed. Behavioral Neurobiology of Schiozphrenia and Its Treatment. Berlin: Springer; 2010:391-433.
17. Distler MG, Opal MD, Dulawa SC, Palmer AA. Assessment of behaviors modeling aspects of schizophrenia in Csmd1 mutant mice. PLoS One. 2012;7:e51235.
18. Barkus C, Feyder M, Graybeal C, et al. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder? Neuropharmacology. 2012;62:1263-1272.
19. Vardigan JD, Huszar SL, McNaughton CH, Hutson PH, Uslaner JM. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol Biochem Behav. 2010;95:223-229.
20. Karlsson RM, Tanaka K, Saksida LM, Bussey TJ, Heilig M, Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology. 2009;34:1578-1589.
21. Berlin I, Givry-Steiner L, Lecrubier Y, Puech AJ. Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. Eur Psychiatry. 1998;13:303-309.
22. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13:28-35.
23. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. Schizophr Bull. 2010;36:1061-1062.
24. Morris SE, Cuthbert BN. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci. 2012;14:29-37.
25. Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014;171:395-397.
26. Green MF, Horan WP, Barch DM, Gold JM. Effort-based decision making: A novel apprach for assessing motivation in schizophrenia. Schizophr Bull.
27. Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004;363:978-988.
28. HODOS W. Progressive ratio as a measure of reward strength. Science. 1961;134:943-944.
29. Barnes SA, Der-Avakian A, Markou A. Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol. 2014;24:744-758.
30. Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA, Ruparel K. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. Schizophr Bull. 2014;40:1328-1337.
31. St Onge JR, Abhari H, Floresco SB. Dissociable contributions by prefrontal D1 and D2 receptors to risk-based decision making. J Neurosci. 2011;31:8625-8633.
32. Aberman JE, Salamone JD. Nucleus accumbens dopamine depletions make rats more sensitive to high ratio requirements but do not impair primary food reinforcement. Neuroscience. 1999;92:545-552.
33. Markou A, Salamone JD, Bussey TJ, et al. Measuring reinforcement learning and motivation constructs in experimental animals: relevance to the negative symptoms of schizophrenia. Neurosci Biobehav Rev. 2013;37:2149-2165.
34. Salamone JD, Correa M. Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res. 2002;137:3-25.
35. Salamone JD, Correa M, Farrar A, Mingote SM. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl). 2007;191:461-482.
36. Izquierdo A, Belcher AM. Rodent models of adaptive decision making. Methods Mol Biol. 2012;829:85-101.
37. Barch DM, Carter CS; CNTRICS Executive Committee. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative. Schizophr Bull. 2008;34:613-618.
38. Carter CS, Barch DM, Bullmore E, et al. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry. 2011;70:7-12.
39. Gold JM, Hahn B, Zhang WW, et al. Reduced capacity but spared precision and maintenance of working memory representations in schizophrenia. Arch Gen Psychiatry. 2010;67:570-577.
40. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
41. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006;67(Suppl 9):3-8; discussion 36-42.
42. Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006;8:109-113.
43. Young JW, Geyer MA, Rissling AJ, et al. Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice. Transl Psychiatry. 2013;3:e324.
44. Cocker PJ, Hosking JG, Benoit J, Winstanley CA. Sensitivity to cognitive effort mediates psychostimulant effects on a novel rodent cost/benefit decision-making task. Neuropsychopharmacology. 2012;37:1825-1837.
45. Hosking JG, Cocker PJ, Winstanley CA. Dissociable contributions of anterior cingulate cortex and basolateral amygdala on a rodent cost/benefit decision-making task of cognitive effort. Neuropsychopharmacology. 2014;39:1558-1567.
46. Hosking JG, Floresco SB, Winstanley CA. Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: a comparison of two rodent cost/benefit decision-making tasks. Neuropsychopharmacology. 2015;40:1005-1015.
47. Horan WP, Reddy LF, Barch DM, et al. Effort-based decision making paradigms for clinical trials in schizophrenia: Part 2 - external validity and correlates. Schizophr Bull.
48. Reddy LF, Horan WP, Barch DM, et al. Effort-based decision making paradigms for clinical trials in schizophrenia: Part 1 - psychometric characteristics of five paradigms. Schizophr Bull.
49. Waltz JA, Frank MJ, Robinson BM, Gold JM. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry. 2007;62:756-764.
50. Bari A, Theobald DE, Caprioli D, et al. Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats. Neuropsychopharmacology. 2010;35:1290-1301.
51. Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science. 2006;311:861-863.
52. Frank MJ, Seeberger LC, O'reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science. 2004;306:1940-1943.
53. Waltz JA, Frank MJ, Wiecki TV, Gold JM. Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology. 2011;25:86-97.
54. Whitton AE, Treadway MT, Pizzagalli DA. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry. 2015;28:7-12.
55. Nestor PG, Choate V, Niznikiewicz M, Levitt JJ, Shenton ME, McCarley RW. Neuropsychology of reward learning and negative symptoms in schizophrenia. Schizophr Res. 2014;159:506-508.
56. Paulus MP, Rogalsky C, Simmons A, Feinstein JS, Stein MB. Increased activation in the right insula during risk-taking decision making is related to harm avoidance and neuroticism. Neuroimage. 2003;19:1439-1448.
57. Stopper CM, Floresco SB. What's better for me? Fundamental role for lateral habenula in promoting subjective decision biases. Nat Neurosci. 2014;17:33-35.
58. St Onge JR, Floresco SB. Prefrontal cortical contribution to risk-based decision making. Cereb Cortex. 2010;20:1816-1828.
59. Amitai N, Young JW, Higa K, Sharp RF, Geyer MA, Powell SB. Isolation rearing effects on probabilistic learning and cognitive flexibility in rats. Cogn Affect Behav Neurosci. 2014;14:388-406.
60. Collins AG, Brown JK, Gold JM, Waltz JA, Frank MJ. Working memory contributions to reinforcement learning impairments in schizophrenia. J Neurosci. 2014;34:13747-13756.
61. van den Bos R, Jolles J, van der Knaap L, Baars A, de Visser L. Male and female Wistar rats differ in decision-making performance in a rodent version of the Iowa Gambling Task. Behav Brain Res. 2012;234:375-379.
62. Worthy DA, Hawthorne MJ, Otto AR. Heterogeneity of strategy use in the Iowa gambling task: a comparison of win-stay/lose-shift and reinforcement learning models. Psychon Bull Rev. 2013;20:364-371.
63. Stopper CM, Floresco SB. Contributions of the nucleus accumbens and its subregions to different aspects of risk-based decision making. Cogn Affect Behav Neurosci. 2011;11:97-112.
64. van Enkhuizen J, Geyer MA, Young JW. Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl). 2013;225:661-674.
65. van Enkhuizen J, Henry BL, Minassian A, et al. Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology. 2014;39:3112-3122.
66. Young J, van Enkhuizen J, Geyer M. Dopamine transporter knockdown mice exhibit poorer within-session risk learning in a mouse Iowa Gambling Tasl consistent with bipolar mania patients. American College of Neuropsychopharmacology. 2011; Oral Presentation.
67. Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition. 1994;50:7-15.
68. Rivalan M, Ahmed SH, Dellu-Hagedorn F. Risk-prone individuals prefer the wrong options on a rat version of the Iowa Gambling Task. Biol Psychiatry. 2009;66:743-749.
69. Rivalan M, Coutureau E, Fitoussi A, Dellu-Hagedorn F. Inter-individual decision-making differences in the effects of cingulate, orbitofrontal, and prelimbic cortex lesions in a rat gambling task. Front Behav Neurosci. 2011;5:22.
70. Pizzagalli DA, Sherwood RJ, Henriques JB, Davidson RJ. Frontal brain asymmetry and reward responsiveness: a source-localization study. Psychol Sci. 2005;16:805-813.
71. Vrieze E, Pizzagalli DA, Demyttenaere K, et al. Reduced reward learning predicts outcome in major depressive disorder. Biol Psychiatry. 2013;73:639-645.
72. Heerey EA, Bell-Warren KR, Gold JM. Decision-making impairments in the context of intact reward sensitivity in schizophrenia. Biol Psychiatry. 2008;64:62-69.
73. Ahnallen CG, Liverant GI, Gregor KL, et al. The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Res. 2012;196:9-14.
74. Barr RS, Pizzagalli DA, Culhane MA, Goff DC, Evins AE. A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. Biol Psychiatry. 2008;63:1061-1065.
75. Pergadia ML, Der-Avakian A, D'Souza MS, et al. Association between nicotine withdrawal and reward responsiveness in humans and rats. JAMA Psychiatry. 2014;71:1238-1245.
76. Der-Avakian A, D'Souza MS, Pizzagalli DA, Markou A. Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research. Transl Psychiatry. 2013;3:e297.
77. Young J, Kamenski M, Higa K, Light G, Geyer M, Zhou X. GlyT-1 inhibition attenuates the attentional but not learning or motivational deficits of the Sp4 hypomorphic mouse model relevant to psychiatric disorders [published online ahead of print April 24, 2015]. Neuropsychopharmacology. doi: 10.1038/npp.2015.120.
78. Der-Avakian A, Markou A. Neonatal maternal separation exacerbates the reward-enhancing effect of acute amphetamine administration and the anhedonic effect of repeated social defeat in adult rats. Neuroscience. 2010;170:1189-1198.
79. Salamone JD, Correa M, Nunes EJ, Randall PA, Pardo M. The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav. 2012;97:125-146.
80. Floresco SB, Ghods-Sharifi S. Amygdala-prefrontal cortical circuitry regulates effort-based decision making. Cereb Cortex. 2007;17:251-260.
81. Dalton GL, Phillips AG, Floresco SB. Preferential involvement by nucleus accumbens shell in mediating probabilistic learning and reversal shifts. J Neurosci. 2014;34:4618-4626.
82. Atallah HE, Rudy JW, O'Reilly RC. The role of the dorsal striatum and dorsal hippocampus in probabilistic and deterministic odor discrimination tasks. Learn Mem. 2008;15:294-298.
83. Holroyd CB, Hajcak G, Larsen JT. The good, the bad and the neutral: electrophysiological responses to feedback stimuli. Brain Res. 2006;1105:93-101.
84. Orsini CA, Moorman DE, Young JW, Setlow B, Floresco SB. Neural mechanisms regulating different forms of risk-related decision-making: insights from animal models [published online ahead of print June 11, 2015]. Neurosci Biobehav Rev. doi: 10.1016/j.neubiorev.2015.04.009.
85. Ghods-Sharifi S, St Onge JR, Floresco SB. Fundamental contribution by the basolateral amygdala to different forms of decision making. J Neurosci. 2009;29:5251-5259.
86. Floresco SB, Tse MT, Ghods-Sharifi S. Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharmacology. 2008;33:1966-1979.
87. Young JW, Meves JM, Tarantino IS, Caldwell S, Geyer MA. Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 2011;10:720-733.
88. Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, Orr-Urtreger A. Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Mem. 1998;5:302-316.
89. Kurniawan IT, Seymour B, Talmi D, Yoshida W, Chater N, Dolan RJ. Choosing to make an effort: the role of striatum in signaling physical effort of a chosen action. J Neurophysiol. 2010;104:313-321.
90. Ostlund SB, Maidment NT. Dopamine receptor blockade attenuates the general incentive motivational effects of noncontingently delivered rewards and reward-paired cues without affecting their ability to bias action selection. Neuropsychopharmacology. 2012;37:508-519.
91. Eagle DM, Humby T, Dunnett SB, Robbins TW. Effects of regional striatal lesions on motor, motivational, and executive aspects of progressive-ratio performance in rats. Behav Neurosci. 1999;113:718-731.
92. Wonnacott S, Barik J, Dickinson J, Jones IW. Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci. 2006;30:137-140.
93. Hamada M, Higashi H, Nairn AC, Greengard P, Nishi A. Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons. J Neurochem. 2004;90:1094-1103.
94. Quarta D, Naylor CG, Barik J, Fernandes C, Wonnacott S, Stolerman IP. Drug discrimination and neurochemical studies in alpha7 null mutant mice: tests for the role of nicotinic alpha7 receptors in dopamine release. Psychopharmacology (Berl). 2009;203:399-410.
95. Umbricht D, Keefe RS, Murray S, et al. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2014;39:1568-1577.
96. Lieberman JA, Dunbar G, Segreti AC, et al. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38:968-975.
97. Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013;86:1122-1132.
98. Barch DM, Moore H, Nee DE, Manoach DS, Luck SJ. CNTRICS imaging biomarkers selection: Working memory. Schizophr Bull. 2012;38:43-52.
99. Luck SJ, Ford JM, Sarter M, Lustig C. CNTRICS final biomarker selection: Control of attention. Schizophr Bull. 2012;38:53-61.
100. Young JW, Geyer MA. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol. 2015;29:178-196.
101. Burgdorf J, Wood PL, Kroes RA, Moskal JR, Panksepp J. Neurobiology of 50-kHz ultrasonic vocalizations in rats: electrode mapping, lesion, and pharmacology studies. Behav Brain Res. 2007;182:274-283.
102. Millan MJ, Bales KL. Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative. Neurosci Biobehav Rev. 2013;37:2166-2180.
103. Li YC, Kellendonk C, Simpson EH, Kandel ER, Gao WJ. D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex. Proc Natl Acad Sci U S A. 2011;108:12107-12112.
104. Barr AM, Fiorino DF, Phillips AG. Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat. Pharmacol Biochem Behav. 1999;64:597-604.
105. Bensadoun JC, Brooks SP, Dunnett SB. Free operant and discrete trial performance of mice in the nine-hole box apparatus: validation using amphetamine and scopolamine. Psychopharmacology (Berl). 2004;174:396-405.
106. Young JW, Jentsch JD, Bussey TJ, Wallace TL, Hutcheson DM. Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci Biobehav Rev. 2012;37:2181-2193.